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INTRODUCTION
On 11 March 2020, the World Health Organisation (WHO) 
declared the novel beta coronavirus disease 2019 (COVID-19), 
caused by the coronavirus SARS-CoV-2, as a global pande-
mic.(1) As of 1 June 2020, this pandemic has infected more than 
6 million people and killed a sobering 370 000 patients globally. 
On the same date in South Africa, more than 31 000 had been 
infected, with 650 reported deaths.(2)
With no available cure or viable vaccine in sight for at least 
another 12 months, it is evident that all clinicians need to 
learn how to manage this disease optimally and to timeously 
share knowledge and novel therapeutic insights as they 
develop. Furthermore, available evidence indicates that 
COVID-19 is associated with increased morbidity and mortality 
in patients with existing cardiovascular disease and other co-
morbidities.(3-5) These patients have been reported to fre-
quently require intensive care therapies and monitoring.(6) 
Common co-morbidities such as hypertension, diabetes, lung 
disease and obesity have also been implicated.(7) Moreover, all 
of these are also important aetiologies for heart failure.
Heart failure is a common clinical syndrome whereby the heart 
is no longer able to pump an adequate cardiac output to meet 
the body’s physiological and metabolic needs. Patients present 
with typical signs and symptoms such as exertional dyspnoea, 
pedal oedema, a raised jugular venous pressure and a third 
heart sound.(8) In sub-Saharan Africa, the common causes of 
heart failure are hypertension, ischaemic heart disease and 
idiopathic dilated cardiomyopathy.(9) The first two aetiologies 
tend to be associated with advanced age and the metabolic 
syndrome, of which all have been reported to confer poor 
outcomes in SARS-CoV-2 infected patients.(3,5,6) In this narrative 
review, we discuss currently available data on the pathobiology 
of COVID-19 and heart failure, with a focus on the clinical 
presentation and multidisciplinary principles of management.
THE PATHOBIOLOGY OF COVID-19 AND 
HEART FAILURE
The novel beta coronavirus, SARS-CoV-2, is a positive strand 
RNA virus belonging to the family Coronaviridae.(10) This family 




Acute and chronic heart failure patients have a 2- to 
3-fold increased risk of complicating with severe 
COVID-19, and these patients tend to have multiple co-
morbidities which are the primary aetiologies for the 
heart failure clinical syndrome. Furthermore, the inci-
dence and prevalence of heart failure increases with 
advanced age, and advanced age is an independent risk 
factor for poor prognosis and mortality. The SARS-
CoV-2 infection also has multiple mechanisms that 
cause acute heart failure and precipitate acutely 
decompensated chronic heart failure. Additionally, 
the optimal management of these patients has been 
marred with the controversy around the use of the 
renin-angiotensin-aldosterone system blockers. This 
review provides an update on how heart failure patients 
should be managed during COVID-19 and summarises 
the existing evidence, focusing on heart failure.  
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of viruses has been responsible for 2 previous epidemics, 
the middle east respiratory syndrome (MERS) and the severe 
acute respiratory syndrome (SARS), which occurred in the 
years 2012 and 2002 - 2003 respectively.(11) Furthermore, 
SAR-CoV-2 has a high nucleotide sequence similarity with 
SARS-CoV, the virus responsible for the SARS epidemic.(10) 
Therefore, a fair amount of our understanding of the current 
virus has been extrapolated from existing data on the SARS 
virus.
THE ROLE OF ANGIOTENSIN CONVERTING 
ENZYME 2 (ACE2)
Corona viruses infect human cells through the aid of their 
“spike proteins” which give them their characteristic “crown”-
like resemblance. These proteins interact with the trans-
membrane angiotensin-converting enzyme 2 (ACE 2) protein 
to enter type 2 alveolar epithelial cells, pericytes, macrophages 
and other cells in the human body expressing these membrane 
proteins. This step is key to the viral transmission, and it is 
facilitated by the cellular serine protease TMPRSS2.(12) There-
fore, infection with SARS-CoV-2 requires the co-expression of 
ACE2 and TMPRSS2 in the same cell type. Some studies have 
suggested that SARS-CoV-2 has a higher affinity for ACE2 
than SARS-CoV, and hypothesise that this feature explains its 
higher basic reproduction rate (R0 = 2 - 2.5).(13) This SARS-
CoV-2 feature is key to its virulence as higher viral loads and 
prolonged virus shedding periods are directly proportional to 
COVID-19 severity and prognosis.(14)
In contrast, patients with heart failure have an initially appro-
priate compensatory neurohormonal response aimed at 
improving cardiac output to meet the body’s metabolic needs. 
Among other actions, the neurohormonal response involves 
activation of the renin angiotensin aldosterone system (RAAS), 
which ultimately causes vasoconstriction, a raised sympathetic 
tone, hyperaldosteronism, cardiac hypertrophy and fibrosis.(15) 
As part of an endogenous negative feedback mechanism, ACE2 
is naturally upregulated in patients with RAAS activation, which 
is seen in heart failure. In the RAAS, ACE2 mediates the 
conversion of angiotensin II to angiotensin I-VII, which has 
vasodilatory and other protective properties for the cardio-
vascular system.(16) Furthermore, the blockage of RAAS with 
the use of angiotensin-converting enzyme inhibitors (ACEi) or 
angiotensin receptor blockers (ARBs) improves heart failure 
morbidity and mortality.(17-19) However, the use of these 
therapies is also suggested to cause an increase in the levels 
of ACE2.(16, 20-22)
Since heart failure and other cardiovascular conditions such as 
hypertension, where RAAS blockers are used, are suggested to 
be associated with elevated ACE2 levels, these co-morbidities 
have been hypothesised to facilitate increased viral transmis-
sion and poor outcomes.(16) However, there are currently no 
data supporting a causal relationship between ACE2 activity 
and the severity of COVID-19. Contrary to this hypothesis, 
SARS-CoV-infected animal models have been used to 
demonstrate the protective effects of ACE2 on the cardio-
vascular system. Viral spike proteins led to down-regulation of 
ACE2, which was associated with worse pulmonary disease 
in mice. These detrimental effects were attenuated by treat-
ment with RAAS blockers.(23)
MECHANISMS OF MYOCARDIAL INJURY 
LEADING TO HEART FAILURE
Several publications indicate that myocardial injury is the most 
common cardiovascular manifestation of COVID-19. The myo-
cardial injury typically manifests as a troponin leak above the 
upper reference limit, which may or may not be associated with 
left ventricular regional wall motion abnormalities or global 
hypokinesia.(3,4) Despite a relatively mild elevation of cardiac 
troponin, the presence of myocardial injury has been associated 
with a worse prognosis.(4)
Early case series of critically ill patients treated in China and the 
United States of America have reported a significant propor-
tion of patients presenting with overt clinical heart failure 
syndrome,(24,25) and this was associated with a very high mortality 
rate in these cohorts, ranging from 40% - 50%.(24,25) A signifi-
cant limitation of these reports is the small sample size and 
the high probability of selection bias. Importantly, recent 
larger case series from China and Italy have not reported a 
high incidence of heart failure.(26, 27) These differences highlight 
the variation in the study methodologies and the high proba-
bility of selection bias. Table I is a summary of published studies 
where the prevalence and outcomes of heart failure in 
COVID-19 patients have been reported.
Potential mechanisms for the myocardial injury, which may 
precipitate acute heart failure or acute decompensated chronic 
heart failure, include direct viral infection and the indirect injury 
of cardiac myocytes. The effects of SARS-CoV-2 cause direct 
cardiac injury mediated by ACE2 downregulation.(16,28) As dis-
cussed above, ACE2 plays a protective role in neurohormonal 
modulation of the cardiovascular system. Hence, when ACE2 
levels are reduced, this leads to direct and indirect myocar-
dial injury.(16)
A significant number of patients with severe COVID-19 have 
been reported to suffer from the systemic inflammatory 
response syndrome (SIRS).(5,24) This deranged immunological 
state is mediated by the virally triggered cytokine storm, which 
causes widespread organ damage and affected patients have 
the potential to further degenerate into multiorgan failure. This 
clinical state is marked by the presence of high levels of cir-
culating pro-inflammatory cytokines associated with micro-
vascular and endothelial dysfunction.(5,24)
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The SARS-CoV-2 infection has also been implicated in causing 
a myocardial oxygen supply-demand mismatch. This state exists 
when there is an increased cardiometabolic demand caused by 
the systemic infection occurring simultaneously with worsening 
hypoxia driven by the viral acute respiratory syndrome. Ulti-
mately, this leads to myocardial injury via a type 2 myocardial 
infarction mechanism.(29) The virus has also been reported to 
potentially destabilise atherosclerotic plaques through the 
deranged systemic inflammatory response and the cytokine 
storm.(30) Both these mechanisms of clinical and subclinical 
myocardial injury may be responsible for the acute deterioration 
of heart failure patients.
Also, COVID-19 causes coagulation abnormalities. These mani-
fest as a disseminated intravascular coagulation (DIC) pheno-
type or overt pulmonary embolism.(31) These states may further 
complicate with microvascular dysfunction impairing myocar-
dial perfusion or precipitate acute right heart failure from a 
massive pulmonary embolism.(24,32) Elevated fibrin degradation 
products and increased D-dimer levels are associated with 
these clinical scenarios and indicate a poor clinical prognosis.(24)
Myocardial injury leading to heart failure may also occur from 
the potential therapies for COVID-19 (Table II). Knowledge of 
the cardiovascular effects of these molecules has been gathered 
over time, where these drugs have been used as immuno-
suppressant therapies (chloroquine/hydroxychloroquine and 
tocilizumab) and Human Immunodeficiency Virus (HIV) infec-
tion therapies (lopinavir/ritonavir). Of note, the antimalarial 
therapies have been reported to cause heart failure in 26.8% 
of patients on chronic treatment.(33) Figure 1 summarises the 
mechanisms of myocardial injury leading to acute heart failure. 
CLINICAL PROFILES 
The clinical presentation of heart failure in COVID-19 infected 
patients may vary depending on the mechanism of cardiac 
injury (described above) and the presence of underlying cardio-
vascular disease. Due to an overlap in presenting symptoms and 
signs, it may be difficult to clinically distinguish between heart 
failure and respiratory disease in these patients. Potential clinical 
scenarios that may be encountered are described in Table III 
and include the following:
 ■ Acute “de novo” heart failure as a result of direct (acute 
myocarditis) or indirect (cytokine-mediated cardiomy-
opathy) myocardial injury from COVID-19 infection. 















China  274 0.4 62 (44 - 77) 62 34 17 Chen, et al.(51)
Italy   99 21 67 ± 12 81 Inciardi, et al.(34)
Italy 6 272 5.1 66 ± 14 55 54.2 15.8 Mancia, et al.(52)
Asia, Europe, 
North America
8 910 2.1 49 ± 16 60 26.3 14.3 Mehra, et al.(50)
USA 12 594 6.2 49 (34 - 63) 42 34.6 18 Reynolds, et al.(53)
China     416 4.1 64 (21 - 95) 49 30.5 14.4 Shi, et al.(4)
*Median (interquartile range) or mean ± standard deviation. USA = United States of America.
TABLE II: Cardiovascular effects of COVID-19 therapies.
Class Drug Side effects Toxicities Use with caution or avoid














QT and PR interval 
prolongation













 ■ Acute heart failure secondary to a cardiac event (e.g. acute 
coronary syndrome, stress-induced cardiomyopathy, atrial 
or ventricular arrhythmia) precipitated by COVID-19 
infection.
 ■ Acute decompensated chronic heart failure precipitated 
by COVID-19 infection, or other factors associated with 
COVID-19 infection (e.g. acute kidney injury), in patients 
with underlying structural heart disease (hypertensive heart 
disease with heart failure, ischaemic left ventricular dys-
function, cardiomyopathy, valvular heart disease, congenital 
heart disease, pericardial disease and cor-pulmonale).
 ■ Acute right-sided heart failure secondary to pulmonary 
embolism in COVID-19 infected patients. 
























Acute heart failure clinical syndrome
SARS-CoV-2 infection (severe COVID-19 disease)
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TABLE III: Clinical presentations of heart failure in COVID-19 patients.
AHF secondary to 
myocardial injury from 
COVID-19 infection 































with viral symptoms 
(± cytokine storm); 
fulminant heart failure 
± cardiogenic shock; 
± chest pain
Chest pain 
syndrome with AHF 
± cardiogenic shock;
Tachyarrhythmias may 
present with AHF and 
new onset palpitations, 
and/or syncope
Worsening HF 
symptoms such as 
progressive effort 
intolerance, orthopnea, 
PND and peripheral 
oedema; new-onset 
arrhythmias
Acute dyspnoea; chest 
pain; ± collapse with 
hypotension or 
cardiogenic shock; 
right-sided HF; hypoxia; 
absence of pulmonary 
oedema
Viral symptoms such as 
fever, cough, shortness of 
breath, myalgia; hypoxia
Biomarkers(55)
Troponin Mild-moderate troponin 
elevation (hs-TnT 
>50pg/ml); normal 
troponin does not 
exclude myocarditis
ACS - marked 
troponin elevation; 
Arrhythmias may be 
associated with a mild 
troponin leak
Mild troponin elevation; 
or normal troponin level
May be elevated (mild) Troponin levels should 




Borderline or elevated* Borderline or elevated* Elevated*
(Relative to baseline 
levels in chronic HF 
patients)
May be elevated* Usually not elevated*






Acute HF; including 
central, peri-hilar bilateral 
GGO with peripheral 
sparing (“batwing 
distribution”); interlobular 
septal thickening (Kerley 
B lines); pleural effusions; 
peri-bronchial cuffi ng
Acute HF; including 
central, peri-hilar bilateral 
GGO with peripheral 
sparing (“batwing 
distribution”); interlobular 
septal thickening (Kerley 
B lines); pleural effusions; 
peri-bronchial cuffi ng
Typical features of acute 
HF (central, peri-hilar 





peri-bronchial cuffi ng); 
Additional features seen 
in chronic HF including 
upper lobe blood 
diversion; azygos vein 
distension; cardiomegaly
Acute PE; enlarged 
pulmonary artery 
(Fleischer sign); regional 
oligaemia (Westermark 
sign); peripherally located 
wedge-shaped opacity 
(Hampton hump); and 
non-specifi c signs 
including pleural effusion, 
elevated diaphragm, 
vascular redistribution; 
chest radiograph may 
be normal
Typical:
Peripheral bilateral GGO 
± consolidation; 
multifocal GGO with 
rounded morphology 
Intermediate:
Absence of typical 
features AND the 
presence of: multifocal, 
diffuse, peri-hilar or 




Atypical features in HF: 
Unilateral GGO, with or 
without pleural effusions; 
pseudotumor
Atypical features in HF: 
Unilateral GGO, with or 
without pleural effusions; 
pseudotumor
Atypical features in HF: 
Unilateral GGO, with or 
without pleural effusions; 
pseudotumor




septal thickening with 
pleural effusions 
Additional investigations 
ECG Non-localising ST 
changes (typically 
concave in shape) and/or 
non-specifi c 
T wave changes
ACS - ST elevation or 
depression, 
T wave changes, 
Q waves;  
Atrial or ventricular 
arrhythmias














with or without dilatation 
of the ventricles; 
± regional wall motion 
abnormalities, 
± pericardial effusion; 





regional wall motion 
abnormalities, 
± ventricular dysfunction; 
coronary angiogram to 
confi rm obstructive 
CAD (performed 
according to 
ACS guidelines in 
COVID-19 patients)
Echocardiogram: 
structural or functional 
abnormality in keeping 
with underlying diagnosis
CTPA confi rming 
pulmonary embolism; 
V/Q scan should only be 
considered if the chest 
radiograph is completely 
normal














PRINCIPLES FOR CLINICAL MANAGEMENT
Patients infected with COVID-19 primarily present with a 
respiratory disease to healthcare facilities, with a broad spec-
trum of respiratory symptoms which may range from a mild 
flu-like illness associated with fever and malaise, to a more 
severe acute respiratory distress syndrome associated with 
hypoxia.(10,34) Much of these clinical signs and symptoms over-
lap with those seen in the acute heart failure clinical syndrome 
and therefore necessitate the use of available laboratory and 
imaging investigations to diagnose and optimally manage 
evident myocardial dysfunction or overt heart failure. Currently, 
there are no specific treatments for COVID-19, and the 
backbone of hospital care is mainly supportive, and to treat 
any emerging complications. Patients with cardiovascular co-
morbidities also require these conditions to be optimally 
managed to prevent acute deterioration.
INVESTIGATIONS
COVID-19 mediated myocardial injury, which may lead to 
acute heart failure or decompensated chronic heart failure, may 
be asymptomatic and is usually only detected by cardiac 
biomarkers. The most sensitive and readily available cardiac 
biomarkers are the highly sensitive cardiac troponins. These 
markers identify myocardial injury once the troponin levels 
have increased above the upper reference limit (URL).(24,35) The 
higher the troponin leak, the worse the clinical outcomes. This 
association has been especially noted in those with severe 
COVID-19 and those with accompanying cardiovascular co-
morbidities, which has led to an increase in hospital mor-
tality.(4,24,34-36)
N-terminal pro-brain natriuretic peptide (NT-proBNP) is a 
useful cardiac biomarker to rule out heart failure when plasma 
levels are below the heart failure reference limit. However, this 
biomarker is not specific to heart failure only. Therefore, 
elevated NT-proBNP levels may be present in other cardiac 
and non-cardiac conditions (see Table IV).(37) Furthermore, cut-
off levels for NT-proBNP vary according to age and gender, 
and caution must be taken when interpreting natriuretic peptide 
levels in obese patients and those in intensive care with septic 
shock.(38) Concerning COVID-19, a few retrospective obser-
vational studies have demonstrated an association between an 
elevated NT-proBNP and myocardial injury. However, an ele-
TABLE III continued: Clinical presentations of heart failure in COVID-19 patients.
*Natriuretic peptide cut-off values for heart failure in the acute setting: 
NT-proBNP (pg/ml) Brain natriuretic peptide - BNP (pg/ml)
Age (years) <50 50 - 75 >75 All ages
HF unlikely <300 <300 <300 <100
ICU patients - BNP of <150 pg/ml; Obese patients (BMI >35kg/m2) – 
BNP of <50 pg/ml; Renal failure (eGFR <60ml/min) – 
cut-off values for diagnosing HF need to be raised
HF possible (borderline) 300 - 450 300 - 900 300 - 1 800 100 - 400
HF likely >450 >900 >1 800 >400
ACS = acute coronary syndrome, AHF = acute heart failure, BMI = Body Mass Index, BNP = brain natriuretic peptide, CAD = coronary artery disease, 
CMR = cardiovascular magnetic resonance, CT = computed tomography, CTPA = computed tomography of the pulmonary arteries, ECG = electrocardiogram, 
eGFR = estimated glomerular filtration rate, GGO = ground glass opacities, HF = heart failure, hs-TnT = high sensitivity troponin T, ICU = intensive care unit, 
PE = pulmonary embolism, RV = right ventricle, VQ = ventilation-perfusion.






Hypertrophic or restrictive cardiomyopathy
Valvular heart disease
Atrial and ventricular tachyarrhythmias
Heart contusion
Cardioversion 
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vated NT-proBNP was not independently associated with 
morbidity and mortality.(4,36,39)
Another important myocardial manifestation of COVID-19 is 
acute fulminant myocarditis. This entity is not as common as 
myocardial injury; however, infected patients may present with 
cardiogenic shock and require intensive care therapies.(40-42) To 
make a definitive diagnosis one needs to perform an endo-
myocardial biopsy demonstrating myocardial inflammation 
with varying degrees of myocardial necrosis. A less invasive 
investigative strategy is to perform cardiac magnetic resonance 
imaging, which may reveal ventricular wall thickening associ-
ated with oedema.(40-42) Acute myocarditis associated with 
COVID-19 infection is discussed in more detail in another 
manuscript in this journal issue, and is beyond the scope of 
this paper.
Other routine heart failure clinical investigations that may add 
value include the electrocardiogram, which is mostly normal 
or has non-specific changes. Its importance is realised when 
unsuspected electrolyte abnormalities, prolonged QT syn-
dromes and new-onset tachyarrhythmias are revealed. The 
chest X-ray is another readily available clinical test that may aid 
in excluding pulmonary disease and may reveal cardiomegaly 
and/or bilateral pleural effusions in keeping with heart failure. 
The transthoracic echocardiogram adds value to confirm 
regional wall motion abnormalities and to determine left ven-
tricular systolic function. It is not necessary for every COVID-19 
patient with respiratory symptoms to receive an echocardio-
gram, but  this investigation should rather be reserved for cases 
where it may alter the management strategy. Furthermore, 
every precaution should be taken to prevent equipment con-
tamination from the patient and infection of the clinical staff. 
Ideally, a dedicated echocardiogram machine should be 
reserved for those with COVID-19, in order to minimise the 
risk of equipment contamination.
MEDICATIONS
As a general rule, the same guideline-recommended treatment 
strategies for acute and chronic heart failure apply in the treat-
ment of patients with and without COVID-19.(43) As per clinical 
guidelines, patients living with heart failure should ideally have 
an annual influenza vaccine and take every precaution to follow 
current recommended protective measures to prevent SARS-
Cov-2 infection.(44,45) Standard protective measures aimed at 
preventing COVID-19 transmission include wearing a facemask 
in public spaces, social distancing, regular handwashing with 
soap and water or the use of alcohol based hand sanitisers. 
Those who are in the New York Heart Association (NYHA) 
functional class I-II, and are ambulatory, should ideally minimise 
their routine hospital visits to reduce their risk of contracting 
the virus. Where available, the use of telemedicine may be an 
appropriate substitute to facilitate the follow-up and review of 
stable ambulatory heart failure patients. However, unstable and 
acutely decompensated patients should present themselves for 
medical review at their local health facility, as infection with 
SARS-CoV-2 may precipitate the acute decompensated heart 
failure state.
Guideline-directed medical therapy should be continued in 
chronic heart failure patients.(43) Foundational therapies, namely 
beta blockers, ACE inhibitors or ARBs, mineralocorticoid 
receptor antagonists, sacubitril/valsartan and recently the 
SGLT2 inhibitors, should all be continued and up-titrated to 
target dosage. As briefly discussed above, despite the con-
troversy around the RAAS blockers, there are still no data to 
support the discontinuation of ACEi or ARBs. Yet some 
observational studies have demonstrated the protective effects 
of ACEi and ARBs in severe COVID-19.(46-50) Clinicians and 
patients must also consider that all principal heart failure 
therapies have compelling randomised controlled trial data 
showing significantly improved morbidity and mortality out-
comes in heart failure with reduced ejection fraction. The use 
of these therapies should not be withdrawn, as this may pre-
cipitate acute decompensation.
CONCLUSION
The SARS-CoV-2 virus infection has worse outcomes in elderly 
patients with multiple co-morbidities. Heart failure is one of the 
co-morbidities with poorer outcomes and therefore the care of 
these patients should be optimised to minimise the risk of 
infection with the virus and to anticipate potential complications 
in those infected – to manage them timeously before deteri-
oration. The use of ACEi and ARBs is still recommended, and 
all heart failure patients should be initiated, up-titrated, and 
continue taking these lifesaving therapies. Once patients have 
been diagnosed with de novo myocardial involvement, they 
should ideally be followed up to ensure that they do not 
deteriorate to overt global hypokinesia and the heart failure 
clinical syndrome.
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